The FBI has issued a warning about counterfeit versions of compounded weight loss drugs, which have been found to contain "unknown drugs, hig ...

The FDA wants to end bulk production of copycat versions of weight loss drugs; telehealth companies and compounding ...

Ozempic also has a notable effect on weight loss. One study comparing a weekly semaglutide injection to a placebo ... For weight loss, Hers offers access to a type of metformin called metformin ...

The company said it still expected its weight-loss business to bring in $725 million in revenue in 2025, excluding commercially available doses of semaglutide. Hims & Hers is set to continue ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm ...

Hims & Hers is a compounder of the weight loss drug whose shares are often volatile around news regarding shortages of Novo Nordisk’s (NVO) Ozempic and Wegovy injections Eli Lilly’s (LLY ...

Hims & Hers’ weight loss offerings will now mainly include its oral medications and the liraglutide injection, which the company plans to launch in the early second half of 2025. Also ...

While there are other weight loss plans available that prescribe compounded GLP-1 injections, Hers offers access to a more comprehensive approach. If prescribed medicine through Hers, you’ll ...

Hims & Hers shares fell on Tuesday, a day after the company released fourth-quarter results that disappointed on gross margin and outlined changes to its weight loss business. The company reported ...

He attributed growth to subscriber retention and the scaling of personalized solutions, including weight-loss treatments ... for sustained growth. Hims & Hers closed 2024 with strong financial ...

Hims & Hers said it expects between $2.3 billion and $2.4 billion in revenue this year. The company added that it expects its weight loss offerings to generate at least $725 million in revenue ...